Maria Rescigno, Prof

European Institute of Oncology
Milano Italy
Biographical Sketch: Maria Rescigno graduated in Biology in 1990 at the University of Milan. From 1991 to 1994 she worked at the University of Cambridge, UK, in the Department of Biochemistry, as a visiting scholar. From 1995 to 1999, she worked at the National Research Council of Milan where she received her PhD in Pharmacology and toxicology in 1999. From 1999 to 2001 she worked at the University of Milano-Bicocca where she specialized in Applied Biotechnology. Since 2001 she is the director of the Dendritic cell biology and immunotherapy Unit at the Department of Experimental Oncology at the European Institute of oncology. She was the first to show that dendritic cells in the gut actively participate to bacterial uptake. Her major field of interest is the development of new immunotherapy strategies to fight cancer. She authored more than 100 publications in high impact journals including Nature Immunol, Immunity, J. Exp. Med., Science TM. She was nominated EMBO young investigator in 2007. Since 2008 she is visiting professor at the University of Oslo. In 2011 Maria Rescigno won the Avon prize as ‘Woman symbol of the city of Milan’ and was elected EMBO member. From 2014 she is Associate Professor at the University of Milan.

Any personal financial relationships? No

I have disclosed to ICMI all relevant financial relationships, and hereby allow ICMI to disclose this information to learners in print.

I have not and will not accept any additional honoraria, payments or reimbursements beyond that which has been agreed upon directly with ICMI.

I agree to provide educational content and resources in advance for review if requested by ICMI.

1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.

2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).

3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.

4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".

Signed on 03/08/2015 by Maria Rescigno

Papers:
Antigen Uptake and Presentation
F.64 Identification and characterization of the “GUT VASCULAR BARRIER” that is exploited by Salmonella typhimurium for its systemic dissemination
OR.16 The Intestinal Microenvironment Restrict HIV-1 Replication in Human Dendritic Cells.
T.96 The differential role of Thymic stromal lymphopoietin (TSLP) isoforms in intestinal and skin pathologies

	I have disclosed to ICMI all relevant financial relationships, and hereby allow ICMI to disclose this information to learners in print.
	I have not and will not accept any additional honoraria, payments or reimbursements beyond that which has been agreed upon directly with ICMI.
	I agree to provide educational content and resources in advance for review if requested by ICMI.
	1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.
	2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).
	3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.
	4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".